Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)
Status:
Completed
Trial end date:
2021-08-26
Target enrollment:
Participant gender:
Summary
The purpose of this phase 3, open-label, multi-center study is to evaluate the safety and
efficacy of lanadelumab in Japanese participants with HAE Type I or II.